Freedom International Group announced a strategic partnership with Elite Pharm Laboratoires, one of the leading nutritional supplement manufacturers in France. The deal makes FIG one of the company's largest shareholders.

Freedom International Group President Narek Sirakanian said the move is an important part of the company’s strategy in the healthcare sector. The company already has two successful projects in this industry - Project V and CoffeeCell.

The partnership between FIG and Elite Pharm will also strengthen cooperation with Project V, which already manufactures its products at the French facility.

The deal marks a new stage in the development of Elite Pharm Laboratoires. The company plans to double its current production: from 25 million capsules per month to 50 million. This will allow it to reach a target revenue of 50 million euros by 2029.

According to the president of FIG, France is an ideal location for producing nutritional supplements because of its strict quality standards and advanced technology. In addition, thanks to Sessia's IT division, Freedom International Group will be able to implement artificial intelligence technologies to create more effective products and speed up focus group testing.

A shared vision for success

Elite Pharm Laboratoires, founded in 1997, specializes in the development and production of nutraceuticals. The company offers a full service, from research and development to the production of private-label products.

Gerard Strauch, founder and CEO of Elite Pharm, also noted that Freedom International Group's investment will enable the company to elevate its production levels and become a significant player in the European market. He stated that Elite Pharm and Freedom International Group share a common vision: innovation and industrialization are the keys to success.

This partnership therefore confirms both companies' commitment to creating a sustainable and innovative business model focused on people's health and well-being.

Widespread media coverage

The news of the partnership was picked up by more than 180 media outlets in Europe and reached nearly 30 million readers in the first two days after distribution. This confirms the significance of the deal and the interest in driving innovation in the nutraceutical sector.